openPR Logo
Press release

Biosimilar Market to Reach US$ 10.90 Billion by 2021

06-23-2017 09:32 AM CET | Health & Medicine

Press release from: Market Research Engine Report - MRE

The Biosimilar Market is segmented on the lines of its product, application, manufacturing type and regional. Based on product segmentation it covers recombinant non-glycosylated proteins, recombinant glycosylated proteins, recombinant peptides. Based on application segmentation it covers oncology, blood disorders, chronic & autoimmune diseases, growth hormone deficiency, infectious diseases, other applications. Based on manufactured type it covers in-house manufacturing, contract manufacturing organizations.

Browse Full Report: https://www.marketresearchengine.com/biosimilar-market-report

How Big is the Global Biosimilar Market?

The Biosimilar Market is expected to exceed more than US$ 10.90 Billion by 2021 at a CAGR of 26.3% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Samsung Bioepis (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion, Inc. (South Korea), and Biocon Ltd. (India). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Biosimilar Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Table of Contents

1 INTRODUCTION
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Biosimilars Market, By Type of Product
6.1 Introduction
6.2 Recombinant Non-Glycosylated Proteins
6.2.1 Insulin
6.2.2 Recombinant Human Growth Hormone (RHGH)
6.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
6.2.4 Interferons
6.3 Recombinant Glycosylated Proteins
6.3.1 Erythropoietin (EPO)
6.3.2 Monoclonal Antibodies (MABS)
6.3.3 Follitropin
6.4 Recombinant Peptides
6.4.1 Glucagon
6.4.2 Calcitonin
7 Biosimilars Market, By Type of Manufacturing
7.1 Introduction
7.2 In-House Manufacturing
7.3 Contract Manufacturing Organizations
8 Biosimilars Market, By Application
9 Biosimilars Market, By Region
10 Competitive Landscape
11 Company Profiles
11.1 Introduction
11.2 Pfizer Inc.
11.3 Sandoz International GmbH (A Division of Novartis International AG)
11.4 Teva Pharmaceutical Industries Ltd.
11.5 F. Hoffmann-La Roche Ltd.
11.6 Amgen Inc.
11.7 Biocon Ltd.
11.8 Dr. Reddy's Laboratories
11.9 Celltrion Inc.
11.10 Mylan Inc.
11.11 Samsung Bioepis

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine
Contact Person: John Bay
Email: john@marketresearchengine.com
Phone: +1-855-984-1862
Country: United States
Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Market to Reach US$ 10.90 Billion by 2021 here

News-ID: 592838 • Views:

More Releases from Market Research Engine Report - MRE

Nonwoven filter media Market 2019 Outlook, Opportunity and Demand Analysis Repor …
New York, June 15, 2019: The Global Nonwoven Filter Media Market is expected the highest growth during the projected period. Manufacturers widely use this filtration media in air, gas and liquid filtration processes. Growing consumer awareness regarding health issues vis-à-vis product safety, air quality, water purity etc. drives the market. However, an unfavourable regulatory environment, especially concerning applications that involve the use of nonwoven filter media is restricting market growth.
Nuclear Medicine/Radiopharmaceuticals Market is Expected to Exceed US$ 4.5 Billi …
The important factors driving the nuclear medicine market are advances in radiotracers and alpha radio immunotherapy-based targeted cancer treatment. SPECT and PET scans usage has been increasing to detect diseases like cancer which is driving the nuclear medicine market. Raising the incidence of cancer and cardiac ailments are also responsible for growing the nuclear medicine market. The nuclear medicine market is also having some restraints such as strict regulatory and
Antidiabetics Market is Expected to Reach USD 80.0 Billion by 2022
The global antidiabetics market is segmented based on its product which includes thiazolodinediones, glp-agonists, sulphonylureas, dpp-4 inhibitors, sglt-2, alpha-glucosidase inhibitors, biguanides and meglitinides. The insulin is segmented as rapid acting, long acting, premixed, premixed analog, short acting and intermediate acting. The market segments in terms of geographical regions include North America, Europe, Asia-Pacific and Rest of the World (ROW). Browse Full Report @: https://www.marketresearchengine.com/reportdetails/antidiabetics-market How Big is the Global Antidiabetics Market? Global Antidiabetics
Curcumin Market is Expected to Exceed USD 100 Million by 2022
The global curcumin market is segmented based on its applications which include food, cosmetics, pharmaceuticals and others. The market segments in terms of geographical regions include North America, Europe, Asia-Pacific and Rest of the World (ROW). Browse Full Report @: https://www.marketresearchengine.com/reportdetails/curcumin-market How Big is the Global Curcumin Market? Global Curcumin market is anticipated to reach USD 95 million by 2021, Pharmaceutical was leading application segment in global curcumin market accounting over 45% of

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of